# Cell Envelope Biogenesis in Clostridioides difficile

> **NIH NIH R01** · UNIVERSITY OF IOWA · 2024 · $514,249

## Abstract

Project Summary
Clostridioides (Clostridium) difficile infections of the colon strike close to 500,000 people a year in the United
States, leading to nearly 30,000 deaths. The CDC has declared this organism an “urgent” threat to public health,
the highest threat category. C. difficile infections are difficult to treat in large part because the organism forms
dormant spores that survive antibiotic therapy and seed recolonization of the gut when antibiotics are withdrawn.
This problem is exacerbated by the fact that the antibiotics used against C. difficile also kill many of the healthy
gut bacteria, clearing the way for C. difficile to recolonize when spores germinate. Thus, there is a tremendous
need for new drugs that target C. difficile without disrupting the healthy microbiota. The premise of this proposal
is that a deeper understanding of cell envelope biogenesis can pave the way towards developing better ways to
treat C. difficile infections. The cell envelope is a well-validated target for antibiotics, and in C. difficile the
envelope has some unusual features that suggest its assembly requires novel proteins that could be exploited
as targets of C. difficile-selective antibiotics. In Aim 1 we will use genetics, biochemistry and microscopy to
understand the roles and regulation of enzymes that crosslink the peptidoglycan cell wall. These enzymes
captured our attention because in C. difficile the cell wall contains an unusually high percentage of “3-3”
crosslinks as compared to the “4-3” crosslinks that predominate in most bacteria. Our experiments will address
the following questions: Which enzymes are responsible for 3-3 and 4-3 crosslink formation and do they operate
during division, elongation or both? How is the ratio of 3-3 to 4-3 crosslinking regulated? How does C. difficile
benefit from using primarily 3-3 crosslinks? In Aim 2 we will leverage a powerful new gene-silencing tool called
CRISPR interference (CRISPRi) to assign a set of ~50 putatively essential envelope biogenesis genes to more
specific functional pathways. These genes are intrinsically interesting and constitute potential new antibiotic
targets. We will also undertake a detailed analysis of a novel transcriptional regulatory system uncovered in a
pilot version of our proposed screen. Collectively, the lines of investigation to be pursued here will greatly
advance our understanding of C. difficile biology by identifying new proteins involved in assembly of the cell
envelope and revealing how their activities are coordinated to accomplish the complex processes of growth and
division.

## Key facts

- **NIH application ID:** 10843232
- **Project number:** 5R01AI155492-04
- **Recipient organization:** UNIVERSITY OF IOWA
- **Principal Investigator:** Craig D Ellermeier
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $514,249
- **Award type:** 5
- **Project period:** 2021-06-01 → 2026-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10843232

## Citation

> US National Institutes of Health, RePORTER application 10843232, Cell Envelope Biogenesis in Clostridioides difficile (5R01AI155492-04). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10843232. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*